Clinical trial
A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib
NCT02455297 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib
- Lead sponsor
- Bayer
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 24, 2015
- Completion date
- August 31, 2016
- Enrollment
- 4 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.